Next Phase Newsletter

A venture capital firm founded in 2016 with offices in USA and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Japan manages a fund dedicated specifically to life science investments. Though it could largely vary on a deal-by-deal basis, the firm’s initial size of investment is usually around $1M, with a significant portion dedicated to follow-on investments. Geographically, the firm is focused on companies headquartered in Japan and those that are looking to expand into the Japanese market.

The firm is most interested in biotech and digital health technologies. The firm is very interested in emerging therapeutic technologies such as cell and gene therapy, as well as platform technologies. With regards to digital health technologies, the firm is most interested in (i) IT solutions for people in terms of health management, disease prevention, diagnosis, therapy, disease management, and nursing care; (ii) healthcare industry in terms of drug discovery & development, medical information, distribution system by leveraging AI, big data, IoT, VR, etc. The firm is opportunistic in terms of stage, and will seek opportunities that are pre-clinical and beyond.

The firm is actively seeking opportunities in Japan and those that are looking to expand into Japan. The firm will prefer to lead investments in companies headquartered in Japan where they can best leverage their resources and network, but will generally follow larger syndicates for deals outside of Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A UAE registered investment consultancy firm’s core activities involve independent advisory, outsourced CIO, and direct investments. The firm acts as the consultant role to advise global family offices with their investment objectives. The firm looking for investment leads in early-stage life science industry. Companies who are looking to raise their series B – series C rounds would be the sweet spot. The firm typically invests in $5M-25M, which depends on the stage of development. The firm is also open to looking at earlier stage companies but the investment size might vary. The firm is looking for companies in the US (60%), China (20%), UK, Germany, India, and other countries with emerging life science technologies.

The firm is opportunistic in sectors and is willing to consider any indications.

The firm has no specific requirements for companies. The firm might take an observer seat or board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA is interested in a broad range of technology companies, including those in the software, cloud services, IT, and Internet sectors. In the life sciences, the firm will only invest in the healthcare IT sector. The firm invests in late seed to early Series A rounds with a typical investment size ranges from $50,000 to $2M. Investment is typically in form of equity, though convertible loan and other capital structures would be considered as well. The firm will look at investment opportunities across the US with a focus on West Coast.

The firm will make new investments in the healthcare IT sector. The firm is interested in healthcare services and IT companies targeting platform, enterprise software, m-health, solution, data analytics and consumer health. The firm will invest in commercial-stage companies with products or services on the market.

The firm invests in privately held healthcare companies. The firm focuses on companies with annual revenues of between $0.5M and $10M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in the USA focuses on early-stage diagnostics, life science research tools, and biotech-related companies. The firm’s target initial investment size is $500K-$1M, and the firm has made one investment so far. The firm prefers to act as the co-investor with other types of investors such as strategic partners. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early-stage diagnostics, life science research tools, and biotech-related companies. The firm will invest in a limited number of therapeutic opportunities. The firm also has interests in other technology fields. The firm is opportunistic in terms of subsectors and indications. The firm will consider investing in companies that have strong intellectual property protection and provide barriers to competitive entry. The firm also seeks companies with potential large addressable markets, which typically have the potential to generate at least $100M of annual revenues.

The firm seeks a reliable and experienced management team that can bring the concept to market. The firm may take a board seat in applicable cases. The firm aims fundraising CEOs that are driven to deliver exceptional investment returns to both investors and management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An active life sciences accelerator that funds, supports and advances life science technologies from early development through clinical proof-of-concept recently established a joint venture fund to support early-stage innovation. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. The firm has access to capital to support companies from seed investment through Series A and B financings through the firm’s internal resources and the joint venture fund.

The size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the fund can invest directly as a Series A investment along with participation in related Series B investments.  Lastly, this new fund is part of the accelerator’s partner’s umbrella of funds, which can support companies in later-stage private/mezzanine/crossover financings, debt financings, and IPO/follow-on public offerings. The firm is open to global opportunities.

The firm and the newly established fund support opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly, supportive of first-time CEOs, and works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based private investment firm is focused on healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm is open to opportunities across North America and is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.